As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...

Biogen will retain its commercial rights to ... The marketed biosimilars are versions of big-selling brands, including Amgen's Enbrel (etanercept), AbbVie's Humira (adalimumab), Johnson ...

Amgen AMGN will report third-quarter 2024 results ... REGN will report third-quarter 2024 results on Oct. 31 Biogen BIIB has ...

Now, Amgen will need to submit its brief on the ... s requests for preliminary injunctions to block the sale of Biogen and Samsung Bioepis’ Eylea biosim Opuviz and Biocon’s copycat Yesafili ...

Amgen isn’t the only threat to Eylea; two biosimilars from Biocon Biologics and Biogen won approval from the Food and Drug Administration in May. Sandoz and Formycon also secured clearances in ...

Yee acknowledges that while this is a favorable development, Biogen does face certain challenges ... Yee covers the Healthcare sector, focusing on stocks such as Amgen, Gilead Sciences, and Scholar ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

For Amgen, Citi analysts underscore the potential of its obesity and diabetes drug, MariTide, though the firm remains cautious due to competitive pressures in the GLP-1 market. They believe the ...